These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3501960)

  • 1. Immunity to leishmaniasis: what properties delineate a protective antigen?
    Russell DG
    Ann Inst Pasteur Immunol; 1987; 138(5):774-81. PubMed ID: 3501960
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of T-cell-reactive antigens that protect BALB/c mice against Leishmania major.
    Scott P; Pearce E; Heath S; Sher A
    Ann Inst Pasteur Immunol; 1987; 138(5):771-4. PubMed ID: 3501959
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetically determined response mechanisms to cutaneous leishmaniasis.
    Howard JG; Hale C; Liew FY
    Trans R Soc Trop Med Hyg; 1982; 76(2):152-4. PubMed ID: 6980502
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of host-protective and disease-promoting T cells.
    Liew FY
    Ann Inst Pasteur Immunol; 1987; 138(5):749-55. PubMed ID: 3326624
    [No Abstract]   [Full Text] [Related]  

  • 5. Subsets of specific T cells and experimental cutaneous leishmaniasis.
    Louis JA; Pedrazzini T; Titus RG; Muller I; Farrell JP; Kindler V; Vassalli P; Marchal G; Milon G
    Ann Inst Pasteur Immunol; 1987; 138(5):755-8. PubMed ID: 3501956
    [No Abstract]   [Full Text] [Related]  

  • 6. L3T4+ T cells promoting susceptibility to murine cutaneous leishmaniasis express the surface marker Ly-24 (Pgp-1).
    Moll H; Scollay R
    Eur J Immunol; 1989 Feb; 19(2):307-14. PubMed ID: 2467816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of cell-mediated immunity in cutaneous leishmaniasis.
    Liew FY
    Immunol Lett; 1987 Dec; 16(3-4):321-7. PubMed ID: 2895065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
    Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
    J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell subsets and T-cell antigens in protective immunity against experimental leishmaniasis.
    Scott P
    Curr Top Microbiol Immunol; 1990; 155():35-52. PubMed ID: 1968369
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of the major histocompatibility complex in resistance to parasite infections.
    Wassom DL; Kelly EA
    Crit Rev Immunol; 1990; 10(1):31-52. PubMed ID: 2407264
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P; Pearce E; Natovitz P; Sher A
    J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex.
    Kappler JW; Staerz U; White J; Marrack PC
    Nature; 1988 Mar; 332(6159):35-40. PubMed ID: 3126396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indices of the state of the T-system of immunity in experimental cutaneous leishmaniasis in guinea pigs].
    Konovalova SA
    Med Parazitol (Mosk); 1981; 50(6):23-7. PubMed ID: 6976505
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
    J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in vaccines for leishmaniasis.
    Requena JM; Iborra S; Carrión J; Alonso C; Soto M
    Expert Opin Biol Ther; 2004 Sep; 4(9):1505-17. PubMed ID: 15335317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
    Russell DG; Alexander J
    J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
    Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens.
    MacDonald HR; Schneider R; Lees RK; Howe RC; Acha-Orbea H; Festenstein H; Zinkernagel RM; Hengartner H
    Nature; 1988 Mar; 332(6159):40-5. PubMed ID: 3126397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor lymphocyte stimulating (Mls) gene products in mice influence their genetic resistance or susceptibility to induction of autoimmune encephalomyelitis.
    Ben-Nun A; Soffer D
    Eur J Immunol; 1990 Jan; 20(1):195-200. PubMed ID: 1689661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice.
    Titus RG; Ceredig R; Cerottini JC; Louis JA
    J Immunol; 1985 Sep; 135(3):2108-14. PubMed ID: 3926895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.